Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 109777
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109777
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109777
Table 1 Stability of internal standard responses in quality control samples
Internal standard | Retention time | Mass-to-charge ratio (mz) | RSD |
IS1 | 222.6 | 121.0439 | 0.0374 |
IS2 | 159.2 | 133.1057 | 0.0262 |
IS3 | 231.2 | 152.0591 | 0.0662 |
IS4 | 28.5 | 127.0805 | 0.0444 |
IS5 | 160.4 | 127.1428 | 0.0466 |
IS6 | 157.5 | 135.1208 | 0.029 |
Table 2 Basic demographic characteristics in the gastric cancer and control groups
Group | Cases | Age (years) | Sex (male/female) |
Gastric cancer group | 30 | 60.40 ± 9.902 | 19/11 |
Healthy group | 30 | 57.93 ± 11.447 | 16/14 |
t/χ2 | 29.553 | 0.617 | |
P value | 0.386 | 0.432 |
Table 3 principal component analysis model parameters
Model | Type | A | n | R2X (cum) | Title |
Model 1 | PCA | 4 | 67 | 0.559 | Total with QC |
Model 2 | PCA | 4 | 60 | 0.559 | Total |
Model 3 | PCA | 4 | 60 | 0.559 | CK vs DG |
Table 4 Top 10 differential fecal metabolites between the gastric cancer and control groups
Name | VIP value | P value | Fold change | Trend |
Dethiobiotin | 2.148 | 0.000 | 9.229 | Up |
Glycylproline | 1.269 | 0.000 | 3.538 | Up |
Glycine | 1.568 | 0.001 | 5.981 | Up |
Hydroxyisocaproic acid | 1.301 | 0.001 | 3.609 | Up |
Tyramine | 1.640 | 0.002 | 14.039 | Up |
Methionine sulfoxide | 1.263 | 0.002 | 2.579 | Up |
5-Aminopentanoic acid | 1.156 | 0.002 | 3.367 | Up |
Citrulline | 1.071 | 0.002 | 2.692 | Up |
Betonicine | 1.131 | 0.004 | 2.286 | Up |
Formiminoglutamic acid | 1.705 | 0.006 | 10.948 | Up |
Cytidine | 2.080 | 0.000 | 0.154 | Down |
5'-methylthioadenosine | 2.032 | 0.000 | 0.207 | Down |
Trehalose | 1.203 | 0.001 | 0.205 | Down |
Melibiose | 1.203 | 0.001 | 0.205 | Down |
Lotaustralin | 1.591 | 0.001 | 0.270 | Down |
Adenosine | 1.043 | 0.003 | 0.188 | Down |
Inosine | 1.367 | 0.003 | 0.205 | Down |
Ribothymidine | 1.454 | 0.004 | 0.218 | Down |
Raffinose | 1.409 | 0.005 | 0.179 | Down |
Galactinol | 1.356 | 0.008 | 0.108 | Down |
Table 5 Pathway analysis of differential fecal metabolites between the gastric cancer and control groups
Pathway name | Total | Hits | Raw P value | Impact |
Purine metabolism | 92 | 4 | 0.0072593 | 0.01303 |
Cysteine and methionine metabolism | 56 | 3 | 0.011789 | 0.08586 |
Galactose metabolism | 41 | 2 | 0.048471 | 0.06586 |
Lysine degradation | 47 | 2 | 0.061937 | 0.07943 |
Glycine, serine, and threonine metabolism | 48 | 2 | 0.064295 | 0.22194 |
Biotin metabolism | 11 | 1 | 0.092074 | 0.19512 |
Pyrimidine metabolism | 60 | 2 | 0.094814 | 0.02789 |
Arginine and proline metabolism | 77 | 2 | 0.14362 | 0.01997 |
Histidine metabolism | 44 | 1 | 0.32231 | 0.01609 |
Primary bile acid biosynthesis | 47 | 1 | 0.34023 | 0.00822 |
Starch and sucrose metabolism | 50 | 1 | 0.35769 | 0.00944 |
Tyrosine metabolism | 76 | 1 | 0.49167 | 0.01424 |
- Citation: Zhu LH, Jin ZX, Ma YQ, Feng X, Ci CH, Zhou YS, Gu QL, Lan YM, Zhang ZL. Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions. World J Gastrointest Oncol 2025; 17(9): 109777
- URL: https://www.wjgnet.com/1948-5204/full/v17/i9/109777.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.109777